A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD7442 in Healthy Chinese Adults
Latest Information Update: 03 Apr 2023
At a glance
- Drugs Cilgavimab/tixagevimab (Primary) ; Cilgavimab/tixagevimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 30 Mar 2023 Status changed from active, no longer recruiting to completed.
- 01 Jul 2022 New trial record